DeutschNewstral
Article
jdsupra.com on 2018-06-11 19:48
Samsung Bioepis Reports One-Year Follow-Up Results for Trastuzumab Biosimilar
Related news
- Samsung Bioepis Announces Four-Year Follow-Up Data for its Trastuzumab Biosimilar and 24-Week Interim Results from Phase 3 Trial of its Proposed Ranibizumab Biosimilarjdsupra.com
- Samsung Bioepis and Merck Announce U.S. Launch of Trastuzumab Biosimilarjdsupra.com
- New BPCIA Complaint: Genentech Sues Samsung Bioepis Regarding Proposed Trastuzumab Biosimilarjdsupra.com
- Immunex and Samsung Bioepis Seek to Stay Etanercept Biosimilar Litigationjdsupra.com
- FDA Approves Celltrion’s Trastuzumab Biosimilarjdsupra.com
- Samsung Bioepis and Merck Launch Herceptin (trasuzumab) Biosimilar Ontruzant® in U.S.jdsupra.com
- World Health Organization (“WHO”) Prequalifies Biosimilar Trastuzumab – WHO’s First Biosimilarjdsupra.com
- New BPCIA Complaint: Genentech Sues Amgen over Proposed Trastuzumab Biosimilarjdsupra.com
- U.S. Biosimilar Launches: Mylan/Biocon’s Trastuzumab, Sandoz’s Pegfilgrastimjdsupra.com
- Prestige Biopharma Partners with Cipla Ltd. for Trastuzumab Biosimilarjdsupra.com
- Biogen Increases Ownership Stake in Samsung Bioepisjdsupra.com
- Teva and Celltrion Launch Trastuzumab Biosimilar in U.S.jdsupra.com
- EMA Reviews Samsung Bioepis’ Lucentis Biosimilar For Eye Diseasesjdsupra.com
- FDA Accepts Review of Samsung Bioepis and Biogen’s Ranibizumab Biosimilarjdsupra.com
- Samsung Bioepis Receives EU Marketing Authorization For Trastuzumab Biosimilarjdsupra.com
- NeuClone Commences Human Dosing of Biosimilar Trastuzumab in Phase I Clinical Trialjdsupra.com
- FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)jdsupra.com
- FDA Approves Samsung Bioepis’s Trastuzamab Biosimilarjdsupra.com
- Researchers Publish Results Of Biosimilar-Switching Studiesjdsupra.com
- FDA Accepts Application From Samsung Bioepis and Biogen For Lucentis® (ranibizumab) Biosimilarjdsupra.com